Roche (OTCMKTS:RHHBY) Sets New 52-Week High – Should You Buy?

Shares of Roche Holding AG (OTCMKTS:RHHBY) reached a new 52-week high during mid-day trading on Friday. The company traded as high as $61.41 and last traded at $61.11, with a volume of 1,066,831 shares trading hands. The stock had previously closed at $59.62.

Analyst Upgrades and Downgrades

RHHBY has been the subject of a number of analyst reports. Morgan Stanley raised Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price target for the company in a research report on Friday, August 7th. HSBC reiterated a “hold” rating on shares of Roche in a research note on Thursday, September 10th. Zacks Research upgraded shares of Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Oddo Bhf raised shares of Roche to an “outperform” rating in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Roche from a “hold” rating to a “buy” rating in a research note on Friday. Eight equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $60.00.

Roche Trading Up 1.0%

The stock has a 50 day moving average price of $55.04 and a 200 day moving average price of $53.04. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.23.

Hedge Funds Weigh In On Roche

Large investors have recently modified their holdings of the company. Puzo Michael J purchased a new position in Roche in the second quarter worth $1,229,000. North Star Asset Management Inc. purchased a new position in shares of Roche during the 2nd quarter valued at about $1,351,000. S&CO Inc. lifted its position in Roche by 163.0% in the 1st quarter. S&CO Inc. now owns 140,551 shares of the company’s stock worth $6,880,000 after buying an additional 87,107 shares during the last quarter. Opal Capital LLC purchased a new stake in Roche in the first quarter worth approximately $4,448,000. Finally, McIlrath & Eck LLC bought a new position in Roche during the first quarter valued at approximately $39,000.

About Roche

Roche Holding AG is a Switzerland-based healthcare company focused on pharmaceuticals and diagnostics. Founded in 1896 and headquartered in Basel, Roche develops medicines and diagnostic technologies intended to support the prevention, diagnosis and treatment of serious diseases.

The company’s pharmaceutical business concentrates on areas including oncology, immunology, neuroscience, ophthalmology and hematology. Its products include targeted cancer therapies, treatments for multiple sclerosis and hemophilia, and medicines for other specialized conditions.